{"protocolSection": {"identificationModule": {"nctId": "NCT02499887", "orgStudyIdInfo": {"id": "754754"}, "organization": {"fullName": "State University of New York at Buffalo", "class": "OTHER"}, "briefTitle": "Repeat Emergency Department Visits Among Patients With Asthma and COPD", "officialTitle": "Repeat Emergency Department Visits Among Patients With Asthma and COPD"}, "statusModule": {"statusVerifiedDate": "2019-06", "overallStatus": "TERMINATED", "whyStopped": "Exclusion criteria prevented enrollment of adequate # of participants", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-01"}, "primaryCompletionDateStruct": {"date": "2016-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-10", "studyFirstSubmitQcDate": "2015-07-13", "studyFirstPostDateStruct": {"date": "2015-07-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-04-16", "resultsFirstSubmitQcDate": "2019-06-03", "resultsFirstPostDateStruct": {"date": "2019-06-04", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-06-03", "lastUpdatePostDateStruct": {"date": "2019-06-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Heather Lindstrom", "investigatorTitle": "Research Assistant Professor", "investigatorAffiliation": "State University of New York at Buffalo"}, "leadSponsor": {"name": "State University of New York at Buffalo", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the proposed study is to determine whether the addition of inhaled corticosteroids to treatment with oral corticosteroids and albuterol would reduce repeat emergency department (ED) visits among patients treated for acute exacerbations of asthma and COPD discharged from the emergency department to home. The investigators hypothesize that patients treated with inhaled corticosteroids in addition to oral corticosteroids and albuterol will have lower rates of 30-day return visits to the emergency department than those patients treated with oral corticosteroids and albuterol only."}, "conditionsModule": {"conditions": ["Asthma", "COPD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "HEALTH_SERVICES_RESEARCH", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 6, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Standard of Care", "type": "ACTIVE_COMPARATOR", "description": "Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.", "interventionNames": ["Drug: albuterol", "Drug: Prednisone"]}, {"label": "Treatment", "type": "EXPERIMENTAL", "description": "Treatment: 30 day QVAR\u00ae (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.", "interventionNames": ["Drug: beclamethasone dipropionate", "Drug: albuterol", "Drug: Prednisone"]}], "interventions": [{"type": "DRUG", "name": "beclamethasone dipropionate", "description": "Inhaler", "armGroupLabels": ["Treatment"], "otherNames": ["Qvar"]}, {"type": "DRUG", "name": "albuterol", "description": "Inhaler", "armGroupLabels": ["Standard of Care", "Treatment"], "otherNames": ["Ventolin"]}, {"type": "DRUG", "name": "Prednisone", "description": "Oral corticosteroid", "armGroupLabels": ["Standard of Care", "Treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Subjects With a Return Visit to the ED Within 30 Days of ED Discharge", "description": "Subjects' medical records will be reviewed for the 30 day period following ED discharge to determine if they return to the treating ED or another regional ED for treatment of an acute asthma/COPD exacerbation. Regional ED records will be queried by use of data maintained by HEALTHeLINK, our regional health information organization system. This will allow for more complete capture of ED return visits that could be obtained by looking only at a single ED.", "timeFrame": "30 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Treated in the ED at the Erie County Medical Center (ECMC) for acute symptoms of asthma or COPD during the study period\n* Patient age \u2265 18 years\n* Resident of the City of Buffalo or Erie County\n* Discharged to home\n* Patient expresses willingness to return to ECMC or own primary care provider for follow-up visits\n* Able to provide informed consent\n* Able to comprehend English language\n\nExclusion Criteria:\n\n* Received oral or inhaled corticosteroids in the week before ED presentation\n* Presented to the ED primarily for prescription refills\n* Complicated comorbid conditions (e.g. renal disease, cardiovascular disease, CHF, HIV)\n* Admitted to ECMC or discharged to another facility\n* Previously enrolled during a prior visit to the ED during the study period\n* For female patients--pregnant or pregnancy status indeterminate\n* Antibiotics are prescribed to treat current asthma/COPD exacerbation.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Heather A Lindstrom, PhD", "affiliation": "University at Buffalo, Department of Emergency Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Erie County Medical Center", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Standard of Care", "description": "Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid"}, {"id": "FG001", "title": "Treatment", "description": "Treatment: 30 day QVAR\u00ae (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nbeclamethasone dipropionate: Inhaler\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Standard of Care", "description": "Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid"}, {"id": "BG001", "title": "Treatment", "description": "Treatment: 30 day QVAR\u00ae (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nbeclamethasone dipropionate: Inhaler\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}], "measures": [{"title": "Age, Categorical", "description": "Age at presentation to emergency department", "populationDescription": "Information on age of all subjects", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "description": "Age at presentation to emergency department", "populationDescription": "Information on age of all subjects", "paramType": "MEDIAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55", "lowerLimit": "45", "upperLimit": "62"}, {"groupId": "BG001", "value": "57", "lowerLimit": "52", "upperLimit": "61"}, {"groupId": "BG002", "value": "56", "lowerLimit": "45", "upperLimit": "62"}]}]}]}, {"title": "Sex: Female, Male", "description": "Sex of all enrolled subjects", "populationDescription": "Sex of all enrolled subjects", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Subjects With a Return Visit to the ED Within 30 Days of ED Discharge", "description": "Subjects' medical records will be reviewed for the 30 day period following ED discharge to determine if they return to the treating ED or another regional ED for treatment of an acute asthma/COPD exacerbation. Regional ED records will be queried by use of data maintained by HEALTHeLINK, our regional health information organization system. This will allow for more complete capture of ED return visits that could be obtained by looking only at a single ED.", "populationDescription": "Study was discontinued due to low enrollment. No 30 day return visit data was collected.", "reportingStatus": "POSTED", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Standard of Care", "description": "Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid"}, {"id": "OG001", "title": "Treatment", "description": "Treatment: 30 day QVAR\u00ae (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nbeclamethasone dipropionate: Inhaler\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Enrolled patients were contacted within 72 hours of ED discharge. Subjects were asked to describe how they were taking study medications and whether or not they were experiencing any side effects of the medication.", "description": "Adverse event description does not differ.", "eventGroups": [{"id": "EG000", "title": "Standard of Care", "description": "Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}, {"id": "EG001", "title": "Treatment", "description": "Treatment: 30 day QVAR\u00ae (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days\n\nSpacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.\n\nbeclamethasone dipropionate: Inhaler\n\nalbuterol: Inhaler\n\nPrednisone: Oral corticosteroid", "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Heather Lindstrom", "organization": "UBMD Emergency Medicine", "email": "hlindstrom@ecmc.edu", "phone": "716-898-4564"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000004630", "term": "Emergencies"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M7796", "name": "Emergencies", "asFound": "Emergency", "relevance": "HIGH"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000011241", "term": "Prednisone"}, {"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018931", "term": "Antineoplastic Agents, Hormonal"}, {"id": "D000000970", "term": "Antineoplastic Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M14121", "name": "Prednisone", "asFound": "Min", "relevance": "HIGH"}, {"id": "M4800", "name": "Beclomethasone", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20966", "name": "Antineoplastic Agents, Hormonal", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}]}}, "hasResults": true}